Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.62 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084089 | 0.90 | MET (0.78) | METNQO2GPR119 | |
| SCHEMBL2489896 | 0.90 | MET (0.61) | METNQO2CHEK2 | |
| SCHEMBL2535395 | 0.90 | MET (0.65) | METNQO2 | |
| SCHEMBL12106973 | 0.90 | MET (0.60) | METNQO2GPR119SLC2A1 | |
| SCHEMBL2455889 | 0.89 | MET (0.78) | METNQO2 | |
| SCHEMBL12216835 | 0.84 | MET (0.72) | METNQO2 | |
| SCHEMBL2455548 | 0.82 | MET (0.79) | METNQO2 | |
| SCHEMBL12547517 | 0.81 | GPR119 (0.52) | METNQO2CHEK2GPR119SLC2A1 | |
| SCHEMBL2455804 | 0.81 | MET (0.72) | METNQO2 | |
| SCHEMBL13181028 | 0.81 | MET (0.60) | METNQO2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MET, TYRO3, ERBB2 | MET 1/4885NQO2 600/4885CHEK2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.